Menu
Publications

COVID-19 Vaccines Portfolio Simulation

The R&D portfolio block predicts the likelihood of COVID-19 vaccines approval and their allocation across technology platforms.

Book Your Consultation

Simulation of the portfolio of COVID-19 vaccines

A portfolio simulator has been developed for effective planning of the COVID-19 vaccines portfolio to answer the following questions: 

  • How can COVID-19 vaccine portfolio outcome, risk, and economic impact on global GDP be forecasted?
  • What is the risk of delivering the COVID-19 vaccine at the end of 2020?
  • How to mitigate production risk to minimize world vaccination time?

The model includes two major blocks – R&D portfolio and manufacturing. The outcome of the manufacturing block is the likelihood of meeting vaccine demand worldwide.

Various risk mitigation strategies were analyzed

  • Increasing manufacturing capacity
  • Additional funding for the most successful vaccines to compress and overlap clinical trial cycle times to increase the likelihood of meeting vaccine demand and minimize global vaccination time.

Email

info@orbeeconsulting.com

Join Our Newsletter Now

Register now to get updates on promotions…

ORBee Consulting offers tools for strategic and operational planning in the biopharmaceutical industry, leveraging operations research techniques for optimization, simulation, statistical analysis, and analytical decision-making.

Quick Links

Menu

Services

Menu

Contract

© Copyright MAVENUP 2024 All Right Reserved.

terms of use    |    privacy policy